Icotyde

(Icotrokinra)

Phase 3Small molecule

Johnson & Johnson

Icotyde is one of 29 small molecule programs targeting Colitis, Ulcerative. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Patents

Pipeline

Status by Indication[3][1]

Indication

Colitis, UlcerativeRecruiting

Crohn DiseaseRecruiting

Arthritis, PsoriaticActive, not recruiting

Colitis, UlcerativePhase 3

Recruiting

Crohn DiseasePreclinical

Recruiting

Arthritis, PsoriaticPhase 3

Active, not recruiting

Competition

Competitive Landscape

22 competitors in Crohn Disease

#DrugCompanyPhaseTrials

Tremfya

Johnson & Johnson

Approved

4 2

Omvoh

Eli Lilly

Approved

2 3

Stelara

Johnson & Johnson

Phase 3

4 4

Skyrizi

AbbVie

Phase 3

1 5

Medrol

Pfizer

Phase 2

1 6

Entyvio

Takeda

Phase 2

1 7

Rituxan

Roche

Phase 2

1 8

Icotyde

Johnson & Johnson

Phase 3

1 9

Kepivance

SSwedish Orphan Biovitrum

Phase 2

1 10

Alkeran

AApotex Inc.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 3Active, not recruiting

Arthritis, Psoriatic

NCT06878404

Q4 2028

Phase 3Recruiting

Arthritis, Psoriatic

NCT06807424

Q1 2032

Phase 3Recruiting

Colitis, Ulcerative

NCT07196748

Q4 2032

PreclinicalRecruiting

Crohn Disease

NCT07196722

Clinical

Trials by Indication[1]

Arthritis, Psoriatic2 trials

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-naïve Participants With Active Psoriatic Arthritis

Active, not recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06878404·552 enrolled

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety of JNJ-77242113 for the Treatment of Biologic-experienced and Biologic-naive Participants With Active Psoriatic Arthritis

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT06807424·750 enrolled

Colitis, Ulcerative1 trial

A Phase 3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol in Adults With an Open Label Study in Adolescents to Evaluate the Efficacy and Safety of Induction and Maintenance Therapy With Icotrokinra in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Phase 3·NCT07196748·882 enrolled

Crohn Disease1 trial

A Phase 2b/3 Randomized, Double-blind, Placebo-Controlled, Parallel Group, Multicenter Protocol to Evaluate the Efficacy and Safety of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease

Recruiting· Johnson & Johnson logo

Johnson & Johnson·Preclinical·NCT07196722·1,092 enrolled

Regulatory

FDA Approval Timeline[4]

Mar 17, 2026

ICOTYDE

NDA NDA220149

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Icotrokinra. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Icotrokinra compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Icotrokinra. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (NDA NDA220149). U.S. Food & Drug Administration.
[5]
FDA Orange Book — Patent and exclusivity data for Icotyde. U.S. Food & Drug Administration.
[6]
SEC EDGAR — Johnson & Johnson company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Johnson & Johnson

Patent Landscape[5]

Patent Cliff

Jul 12, 2039

Earliest patent expiration — generic entry possible after this date

Patent #Expires

12552836Jul 12, 2039

11845808Jan 14, 2041

11939361Nov 19, 2041

Icotyde

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Q4 2028

Q1 2032

Q4 2032

Trials by Indication[1]

Arthritis, Psoriatic2 trials

Colitis, Ulcerative1 trial

Crohn Disease1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Patent Landscape[5]

Related News